Sentiment Trading

Sanofi has acquired Blueprint Medicines for $9.5 billion, marking a significant expansion of its presence in the rare immunological disease sector and positioning the company as a leader in the treatment of these conditions.

Sanofi’s experimental COPD treatment Itepekimab showed mixed results in clinical trials, with one study meeting its primary endpoint but the other failing to do so.

Sanofi SA kicked off 2025 with a strong performance, reporting a 10.8% increase in revenue and exceeding expectations, driven by the success of its flagship product Dupixent and other new pharmaceutical launches.